Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer

The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Menyhárt, Otília, Pongor, Lőrinc Sándor, Győrffy, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331584/
https://www.ncbi.nlm.nih.gov/pubmed/30670970
http://dx.doi.org/10.3389/fphar.2018.01522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331584/
https://www.ncbi.nlm.nih.gov/pubmed/30670970
http://dx.doi.org/10.3389/fphar.2018.01522

Ejemplares similares